Susquehanna International Group, LLP 89bio, Inc. Put Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	SELL	$7.03 - $10.05 $2.59 Million - $3.7 Million	-368,000 Reduced 88.12%	49,600 $380,000
Q3 2024 Nov 14, 2024	SELL	$7.36 - $9.66 $134,688 - $176,778	-18,300 Reduced 4.2%	417,600 $3.09 Million
Q2 2024 Aug 15, 2024	SELL	$7.31 - $10.9 $77,486 - $115,540	-10,600 Reduced 2.37%	435,900 $3.49 Million
Q1 2024 May 07, 2024	SELL	$8.13 - $13.77 $228,453 - $386,937	-28,100 Reduced 5.92%	446,500 $5.2 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $161,172 - $387,926	24,200 Added 5.37%	474,600 $5.3 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $722,880 - $931,680	-48,000 Reduced 9.63%	450,400 $6.95 Million
Q2 2023 Aug 11, 2023	BUY	$14.15 - $22.03 $2.24 Million - $3.49 Million	158,200 Added 46.5%	498,400 $9.44 Million
Q1 2023 May 16, 2023	BUY	$10.48 - $16.94 $3.07 Million - $4.97 Million	293,300 Added 625.37%	340,200 $5.18 Million
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $5,520 - $12,730	-1,000 Reduced 2.09%	46,900 $597,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $144,658 - $335,300	47,900 New	47,900 $277,000

173

125M

78.7K

979K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $525M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.